PGEN NASDAQ
Precigen, Inc.
1W: -10.0%
1M: -21.2%
3M: +12.8%
YTD: +43.7%
1Y: +42.0%
3Y: +480.2%
5Y: +27.6%
$6.15
+0.11 (+1.82%)
Weekly Expected Move ±9.8%
$5
$6
$6
$7
$7
Credit Risk of going bust: higher than 53% of companies Debt: 4.3% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.04 (down 99.3%), Precigen, Inc. would be worth roughly what it owes.
Total debt $98.3M against a stock market value of $2.20B.
Distance to default 4.83 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $46.9M (short-term plus half of long-term), stock volatility 76.7%; Altman Z'' -46.02. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.04 (down 99.3%), Precigen, Inc. would be worth roughly what it owes.
Total debt $98.3M against a stock market value of $2.20B.
Distance to default 4.83 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $46.9M (short-term plus half of long-term), stock volatility 76.7%; Altman Z'' -46.02. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
9 relationships6
As Filer
counterparties named
3
As Counterparty
mentioned by others
4
Rel. Types
2022-03-17
Earliest Filing
2025-08-18
Latest Filing
acquirer: 2
partner: 2
supplier: 1
target: 1
Counterparties (Filed by PGEN)
6 relationshipsCompanies named in PGEN's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Catalent Maryland, Inc. | — | supplier | Precigen, Inc. entered into a Commercial Supply Agreement for Catalent to perform analytical, development, processing, v | 2025-08-18 | View |
| Innovator 21, LLC | — | acquirer | Acquired assets including IP and royalty rights for FCX-007 from Precigen | 2024-12-26 | View |
| Paragon Biosciences, LLC | — | partner | Affiliate of Innovator 21, LLC and parent of Castle Creek Biosciences | 2024-12-26 | View |
| Castle Creek Biosciences, LLC | — | partner | Portfolio company of Paragon; developer of FCX-007 and former collaborator with Precigen | 2024-12-26 | View |
| Trans Ova Genetics, L.C. | — | target | Wholly-owned subsidiary of Precigen, Inc. sold in a $170 million cash transaction. | 2022-07-05 | View |
| Spring Bidco LLC | — | acquirer | Delaware limited liability company that agreed to purchase 100% of Trans Ova Genetics, L.C. | 2022-07-05 | View |
Mentioned As Counterparty
3 mentionsOther companies that named PGEN in their SEC 8-K filings.
| Filed By | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|
| TCRT Alaunos Therapeutics, Inc. | partner | Entered into an Amended and Restated Exclusive License Agreement with Alaunos Therapeutics, Inc. | 2023-04-04 | View |
| TCRT Alaunos Therapeutics, Inc. | partner | Cooperative Research and Development Agreement partner | 2022-06-27 | View |
| TCRT Alaunos Therapeutics, Inc. | partner | Cooperative Research and Development Agreement partner | 2022-03-17 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-08-04 | Earnings Release | View | |
| 2026-06-24 | Officer/Director Change; Shareholder Vote; Exhibits | View | |
| 2026-05-13 | Earnings Release; Exhibits | View | |
| 2026-03-25 | Earnings Release; Exhibits | View | |
| 2025-11-13 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-09-17 | Unregistered Sales of Equity Securities | View | |
| 2025-09-03 | Entry into Material Definitive Agreement; Creation of Direct Financial Obligation; Regulation FD Dis | Agreement | View |
| 2025-08-18 | Entry into Material Definitive Agreement; Financial Statements and Exhibits | Agreement | View |
| 2025-08-18 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-06-30 | Departure/Election of Directors; Appointment of Officers; Submission of Matters to a Vote of Securit | View | |
| 2025-05-14 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-03-19 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-01-16 | Other Events | View | |
| 2024-12-30 | Entry into Material Definitive Agreement; Unregistered Sales of Equity Securities; Material Modifica | Agreement | View |
| 2024-12-26 | Entry into Material Definitive Agreement | Agreement | View |
| 2024-11-14 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-11-07 | Notice of Delisting or Transfer | View | |
| 2024-10-10 | Termination of Material Definitive Agreement | View | |
| 2024-09-23 | Departure/Election of Directors; Appointment of Officers | View | |
| 2024-08-30 | Departure/Election of Directors; Appointment of Officers | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR